Yourgene has indicated FY23 results will be in line with the guidance issued at the time of the fundraise in December, and slightly ahead of our bottom end revenue expectations. Revenues in the core business were up a healthy 19%, with both NIPT and Ranger revenues showing good growth in the period. Progress has been made in reducing the cost base, with further savings to come this year. Cash was £2.8m with negotiations over the disposal of the non-core Taiwan operations progressing. We update o ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY23 update – in line with guidance
- Published:
27 Apr 2023 -
Author:
Chris Glasper -
Pages:
3
Yourgene has indicated FY23 results will be in line with the guidance issued at the time of the fundraise in December, and slightly ahead of our bottom end revenue expectations. Revenues in the core business were up a healthy 19%, with both NIPT and Ranger revenues showing good growth in the period. Progress has been made in reducing the cost base, with further savings to come this year. Cash was £2.8m with negotiations over the disposal of the non-core Taiwan operations progressing. We update o ....